相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biomarkers for Hepatobiliary Cancers
Jean-Charles Nault et al.
HEPATOLOGY (2021)
RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy
Hang-Ping Yao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials
Hang-Ping Yao et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
Ce Li et al.
FRONTIERS IN PHYSIOLOGY (2019)
Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
Hang-Ping Yao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages
Michele L. Babicky et al.
ONCOGENE (2019)
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
Chang-yong Yang et al.
ACTA PHARMACOLOGICA SINICA (2019)
Is irreversible electroporation safe and effective in the treatment of hepatobiliary and pancreatic cancers?
Li-Ming Wu et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2019)
Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
Chen-Yu Hu et al.
FRONTIERS IN ONCOLOGY (2019)
A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers
Makoto Ueno et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
MET-RON dual inhibitor, BMS-777607, suppresses cholangiocarcinoma cell growth, and MET-RON upregulation indicates worse prognosis for intra-hepatic cholangiocarcinoma patients
Chi-Tung Cheng et al.
ONCOLOGY REPORTS (2018)
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Paolo M. Comoglio et al.
NATURE REVIEWS CANCER (2018)
The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma
Yuki Hayashi et al.
ANTICANCER RESEARCH (2016)
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery
Omid Zarei et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma
Hiroyuki Watanabe et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma
Young Wha Koh et al.
TUMOR BIOLOGY (2015)
Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets
Katherine Chang et al.
ONCOTARGET (2015)
The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers
L. M. Privette Vinnedge et al.
ONCOGENE (2015)
Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
Ichiro Kawada et al.
CANCER RESEARCH (2014)
Efficacy of Anti-RON Antibody Zt/g4-Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Liang Feng et al.
CLINICAL CANCER RESEARCH (2014)
The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer
H. Zhao et al.
ONCOGENE (2014)
The RON Receptor Tyrosine Kinase in Pancreatic Cancer Pathogenesis and Its Potential Implications for Future Targeted Therapies
Chang Moo Kang et al.
PANCREAS (2014)
Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-y1)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met
Alan B. Northrup et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents
Sharad Sharma et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors
C. Fialin et al.
LEUKEMIA (2013)
Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
Yi Zou et al.
PLOS ONE (2013)
MSP-RON signalling in cancer: pathogenesis and therapeutic potential
Hang-Ping Yao et al.
NATURE REVIEWS CANCER (2013)
Involvement of Recepteur d'Origine Nantais Receptor Tyrosine Kinase in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma and Its Metastasis
Ya-Ching Chou et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Expression and mutational status of RON in neoplastic lesions of the breast: analysis of MSP/RON signaling in ductal carcinoma in situ and invasive ductal carcinoma
Xiaoliang Ren et al.
APMIS (2012)
RON is not a prognostic marker for resectable pancreatic cancer
Carole M. Tactacan et al.
BMC CANCER (2012)
Ron receptor tyrosine kinase signaling as a therapeutic target
Nancy M. Benight et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Targeting the Met pathway in lung cancer
Astrid Belalcazar et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Macrophage-stimulating protein and calcium homeostasis in zebrafish
Leonie F. A. Huitema et al.
FASEB JOURNAL (2012)
Differential expression of RON in small and non-small cell lung cancers
Rajani Kanteti et al.
GENES CHROMOSOMES & CANCER (2012)
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
Daniel V. T. Catenacci et al.
CANCER BIOLOGY & THERAPY (2011)
Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase
Sunny Guin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu et al.
CLINICAL CANCER RESEARCH (2011)
Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein
Qi Ma et al.
MOLECULAR CANCER (2011)
Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells
Sung-Bum Cho et al.
ONCOLOGY REPORTS (2011)
Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
Ming-Hai Wang et al.
ACTA PHARMACOLOGICA SINICA (2010)
MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
Bo-Sheng Pan et al.
CANCER RESEARCH (2010)
Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers
Jocelyn Logan-Collins et al.
CANCER RESEARCH (2010)
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2010)
Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase
Qi Ma et al.
MOLECULAR CANCER (2010)
From Concept to Reality: The Long Road to c-Met and RON Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
Isabelle Dussault et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma
Jing Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant
Carmen Eckerich et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
Marisa G. Ponzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer
Chung-Ta Lee et al.
DISEASES OF THE COLON & RECTUM (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells
M-H Wang et al.
JOURNAL OF PATHOLOGY (2007)
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression
Ryan M. Thomas et al.
CANCER RESEARCH (2007)
Tyrosine kinase receptor RON in human pancreatic cancer - Expression, function, and validation as a target
E. Ramsay Camp et al.
CANCER (2007)
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene
C Ghigna et al.
MOLECULAR CELL (2005)
Altered exon usage in the juxtamembrane domain of mouse and human RON regulates receptor activity and signaling specificity
X Wei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients
WY Lee et al.
CLINICAL CANCER RESEARCH (2005)
Collaborative activities of macrophage-stimulating protein and transforming growth factor-β1 in induction of epithelial to mesenchymal transition:: roles of the RON receptor tyrosine kinase
D Wang et al.
ONCOGENE (2004)
Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression
C Bardella et al.
CANCER RESEARCH (2004)
Identification and developmental expression of a macrophage stimulating 1/hepatocyte growth factor-like 1 orthologue in the zebrafish
DI Bassett
DEVELOPMENT GENES AND EVOLUTION (2003)
Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential
YQ Zhou et al.
ONCOGENE (2003)
Feline STK gene expression in mammary carcinomas
R De Maria et al.
ONCOGENE (2002)
Role of MED1 (MBD4) gene in DNA repair and human cancer
A Bellacosa
JOURNAL OF CELLULAR PHYSIOLOGY (2001)
Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration
ZQ Xiao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
分享论文
